<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899665</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000483773</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-2111</secondary_id>
    <secondary_id>WSU-12-35-99(M02)</secondary_id>
    <nct_id>NCT00899665</nct_id>
  </id_info>
  <brief_title>Proteases in Patients With Prostate Cancer That Has Spread to the Bone</brief_title>
  <official_title>Proteases in Prostate Cancer Bone Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting and storing samples of bone marrow and tissue from patients to test in&#xD;
      the laboratory may help the study of cancer.&#xD;
&#xD;
      PURPOSE: This laboratory study is comparing proteases (enzymes that break down protein) in&#xD;
      patients with prostate cancer that has spread to the bone with patients who do not have&#xD;
      cancer that has spread to the bone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Examine the roles of proteases and protease-associated molecules in bone metastases in&#xD;
           patients with metastatic prostate cancer.&#xD;
&#xD;
      OUTLINE: Patients undergo bone marrow aspiration and core bone biopsies. Tissues are analyzed&#xD;
      by immunohistochemistry methods, in situ hybridization assays, gelatin zymography and/or&#xD;
      Western blot analysis, and gene profiling analysis in order to visualize and quantitate&#xD;
      protease or protease-related levels.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Expression and activity of proteases and related molecules</measure>
  </primary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Anemia</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous Condition</condition>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>molecular diagnostic method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunoscintigraphy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Diagnosis of metastatic prostate cancer&#xD;
&#xD;
                    -  Patients with documented bone metastases on radiologic imaging studies must&#xD;
                       undergo bone marrow biopsy&#xD;
&#xD;
               -  Male patients ≥ 50 years of age without cancer who are scheduled to undergo bone&#xD;
                  biopsy for other clinically indicated reasons, including any of the following:&#xD;
&#xD;
                    -  Myelodysplasia&#xD;
&#xD;
                    -  Anemia&#xD;
&#xD;
                    -  Monoclonal gammopathy of undetermined significance&#xD;
&#xD;
               -  Male or female patients ≥ 40 years of age without metastatic bone cancer who are&#xD;
                  scheduled to undergo an orthopedic procedure involving removal of bone specimen&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L. Cher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>bone metastases</keyword>
  <keyword>anemia</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

